MBX Biosciences (MBX) Stifel 2026 Virtual Cardiometabolic Forum summary

Strategic overview and pipeline updates

• Precision endocrine peptide platform enables customized peptides with improved potency, durability, and infusion-like PK profiles for differentiated clinical outcomes.

• Lead asset canvuparatide is in phase III for chronic hypoparathyroidism, following successful phase II results showing normalization of serum and urine calcium and improved bone turnover.

• Obesity portfolio includes MBX 4291 (once-monthly GLP-1/GIP co-agonist in phase I), MBX 5765 (amycretin), and MBX 6180 (triple G), with the latter two expected to enter the clinic next year.

• Company is well-capitalized with $420 million in cash, providing runway into 2029 and supporting advancement of multiple programs.

Clinical development highlights

• Canvuparatide phase II demonstrated durable normalization of serum calcium, reduced urine calcium in high-risk patients, and improved bone markers, supporting a best-in-class weekly PTH replacement profile.

• Phase III for canvuparatide starts at 600 mcg with titration from 400–1,600 mcg, aiming to validate phase II results and capture both serum and urine calcium normalization as endpoints.

• Physician and patient feedback highlights strong preference for once-weekly dosing due to convenience and potential for switching from daily injectables.

• Enrollment for canvuparatide phase III expected to complete in H2 2027, with primary endpoint readout likely in H1 2028.

Obesity program differentiation and outlook

• MBX 4291 features a slow, steady PK profile, minimizing burst effects and GI intolerability, with true once-monthly dosing potential (Tmax 26 days).

• Early blinded data show promising tolerability (minimal GI side effects) and weight loss (~7% at 8 weeks), with unblinded cohort C1 data expected in Q4.

• Dose escalation to 180 mg is exploratory, with titration schema designed to mitigate tolerability issues.

• Manufacturing costs for MBX 4291 expected to be commercially feasible, with auto-injector development planned for phase III.